ArticleContemporary clinical trials communications2023

A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.

Tina Roy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.